It is well established that ginkgetin promoted the anticancer effects of cisplatin by inactivating the NRF2/HO-1 axis and enhancing ferroptosis through the downregulation of SLC7A11 and GPX4 expression in NSCLC [83]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.